TY  - JOUR
AU  - Ossami Saidy, Anna
AU  - Peczynski, Christophe
AU  - Thieblemont, Catherine
AU  - Daskalakis, Michael
AU  - Wehrli, Marc
AU  - Beauvais, David
AU  - Finke, Jürgen
AU  - Schorb, Elisabeth
AU  - Vandenberghe, Peter
AU  - Berning, Philipp
AU  - Stelljes, Matthias
AU  - Ayuk, Francis
AU  - Ram, Ron
AU  - Von Bonin, Malte
AU  - Dreger, Peter
AU  - Bethge, Wolfgang
AU  - Kuhnl, Andrea
AU  - Jost, Lasse
AU  - Stölzel, Friedrich
AU  - von Tresckow, Bastian
AU  - Renner, Christoph
AU  - Fuhrmann, Stephan
AU  - Galimard, Jacques-Emmanuelle
AU  - Michel, Eva
AU  - Bazarbachi, Ali
AU  - Balari, Anna Sureda
AU  - Schmitz, Norbert
AU  - Glass, Bertram
TI  - Efficacy and safety of CAR T-cell therapy in patients with primary or secondary CNS lymphoma: A study on behalf of the EBMT and the GoCART coalition.
JO  - HemaSphere
VL  - 9
IS  - 5
SN  - 2572-9241
CY  - Hoboken
PB  - John Wiley & Sons Ltd.
M1  - DKFZ-2025-01056
SP  - e70146
PY  - 2025
AB  - Patients with relapsed or refractory (r/r) primary central nervous system (CNS) lymphoma (PCNSL) or secondary central nervous system (CNS) lymphoma (SCNSL) face a dismal prognosis. They have been excluded from most clinical CAR T-cell trials as investigators feared an increased risk for severe immune effector cell-associated neurotoxicity (ICANS). To investigate the potential of anti-CD19 CAR T-cell therapy (CART) in such patients, we analyzed data of 100 patients with CNS manifestation treated with CART between January 2018 and July 2023 and reported to European Society for Blood and Marrow Transplantation. Median age was 62 years. Of patients, 58
LB  - PUB:(DE-HGF)16
C6  - pmid:40400509
C2  - pmc:PMC12093105
DO  - DOI:10.1002/hem3.70146
UR  - https://inrepo02.dkfz.de/record/301519
ER  -